gabapentin has been researched along with Pain, Procedural in 8 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Pain, Procedural: Pain associated with examination, treatment or procedures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain." | 9.69 | Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023) |
| "The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain." | 5.69 | Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023) |
| "However, it did reduce postoperative pain, which may prove to be a desired attribute of its use, particularly in cases where postoperative pain may be a greater challenge." | 2.94 | Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial. ( Cordes, SMD; Cwiak, CA; Ge, L; Gray, BA; Haddad, LB; Hailstorks, TP; Moore, RH, 2020) |
| "Periprocedural pain has been reported after PNN cryoablation and there are no standardized protocols for optimal in-office local anesthesia." | 1.56 | A preliminary report on the effect of gabapentin pretreatment on periprocedural pain during in-office posterior nasal nerve cryoablation. ( Bradley Strong, E; Gill, AS; Hoshal, SG; Kim, M; Squires, LD; Steele, TO; Suh, JD; Wilson, M, 2020) |
| "Pain is a hallmark of this condition and can be extremely difficult to control." | 1.56 | Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians. ( Chinnadurai, R; Lowney, AC; Miller, M; Sinha, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brant, AR | 1 |
| Reeves, MF | 1 |
| Ye, PP | 1 |
| Scott, RK | 1 |
| Floyd, S | 1 |
| Tefera, E | 1 |
| Lotke, PS | 1 |
| Steele, TO | 1 |
| Hoshal, SG | 1 |
| Kim, M | 1 |
| Gill, AS | 1 |
| Wilson, M | 1 |
| Squires, LD | 1 |
| Bradley Strong, E | 1 |
| Suh, JD | 1 |
| Chaghazardi, S | 1 |
| Hedari, M | 1 |
| Bazargan-Hejazi, S | 1 |
| Mohammadi, R | 1 |
| Ahmadi, A | 1 |
| Natalwala, I | 1 |
| Kiely, J | 1 |
| Kilshaw, A | 1 |
| McKay, G | 1 |
| Chu, V | 1 |
| Phipps, A | 1 |
| Anwar, MU | 1 |
| Yarwood, J | 1 |
| Sandhu, R | 1 |
| Muthayya, P | 1 |
| Sloan, B | 1 |
| Creinin, MD | 1 |
| Schimmoeller, NR | 1 |
| Matulich, MC | 1 |
| Hou, MY | 1 |
| Melo, J | 1 |
| Chen, MJ | 1 |
| Hailstorks, TP | 1 |
| Cordes, SMD | 1 |
| Cwiak, CA | 1 |
| Gray, BA | 1 |
| Ge, L | 1 |
| Moore, RH | 1 |
| Haddad, LB | 1 |
| Chinnadurai, R | 1 |
| Sinha, S | 1 |
| Lowney, AC | 1 |
| Miller, M | 1 |
| Cakirgöz, MY | 1 |
| Demirel, I | 1 |
| Duran, E | 1 |
| Özer, AB | 1 |
| Türkmen, UA | 1 |
| Ersoy, A | 1 |
| Aksu, A | 1 |
| Hancı, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial[NCT03635905] | Phase 4 | 130 participants (Actual) | Interventional | 2017-05-26 | Completed | ||
| Addition of Buprenorphine to Paracervical Block Prior to Osmotic Dilator Insertion for Dilation and Evacuation: A Randomized Controlled Trial[NCT04254081] | Phase 4 | 57 participants (Actual) | Interventional | 2020-05-28 | Completed | ||
| Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial[NCT02944656] | Phase 4 | 114 participants (Actual) | Interventional | 2016-12-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median pain score on a 0 (no pain) to 10 (worst pain) numeric rating scale 1 hour after osmotic dilator insertion assessed via text message (NCT04254081)
Timeframe: 1 hour after osmotic dilator insertion
| Intervention | score on a scale (Median) |
|---|---|
| Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block | 2 |
| 1% Lidocaine Paracervical Block | 3.5 |
Median pain score on a 0 (no pain) to 10 (worst pain) numeric rating scale 2 hours after osmotic dilator insertion assessed via text message (NCT04254081)
Timeframe: 2 hours after osmotic dilator insertion
| Intervention | score on a scale (Median) |
|---|---|
| Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block | 3 |
| 1% Lidocaine Paracervical Block | 3.5 |
Median pain score on a 0 (no pain) to 10 (worst pain) numeric rating scale 6 hours after osmotic dilator insertion assessed via text message (NCT04254081)
Timeframe: 6 hours after osmotic dilator insertion
| Intervention | score on a scale (Median) |
|---|---|
| Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block | 3 |
| 1% Lidocaine Paracervical Block | 3 |
Median pain score on a 0 (no pain) to 10 (worst pain) numeric rating scale at the time of osmotic dilator insertion (NCT04254081)
Timeframe: Assessed immediately after last dilator inserted
| Intervention | score on a scale (Median) |
|---|---|
| Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block | 3.5 |
| 1% Lidocaine Paracervical Block | 4.0 |
"During the Postoperative Day 1 phone call, participants self reported how much they experienced moderate pain in the last 24 hours where 10 = none of the time and 0 = all of the time. Moderate pain was defined according to the perception of each participant." (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 5.2 |
| Placebo Group | 5.2 |
During the Postoperative Day 1 phone call, participants self reported how much they experienced nausea or vomiting in the last 24 hours where 10 = none of the time and 0 = all of the time. Nausea and vomiting were self-reported together as a single outcome. (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 2.3 |
| Placebo Group | 3.2 |
The number of participants reporting filling and using the prescription for ibuprofen postoperatively. During the follow-up phone call on the day after the procedure, participants were asked whether or not they filled the pain medication prescription and if they took any of the medication. (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin Group | 24 |
| Placebo Group | 27 |
"During the Postoperative Day 1 phone call, participants self reported how much they experienced severe pain in the last 24 hours where 10 = none of the time and 0 = all of the time. Severe pain was defined according to the perception of each participant." (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 3.5 |
| Placebo Group | 3.2 |
"Participants reported how much anxiety they were currently experiencing on a 100-point scale where No Anxiety is scored as 0 and Extremely Anxious is scored as 100. Anxiety is reported for the time periods of immediately prior to the procedure, 10 minutes after the procedure, and 30 minutes after the procedure." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 66 | 14 | 4 |
| Placebo Group | 72 | 17 | 2 |
"The primary outcome measure is a pain score using a 100-mm visual analog scale (VAS) measured intraoperatively at time of evacuation. No pain is scored as 0 and worst pain imaginable is scored as 100." (NCT02944656)
Timeframe: During the procedure on Study Day 1
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Paracervical block | Dilation | Aspiration | |
| Gabapentin Group | 63.79 | 64.58 | 67.77 |
| Placebo Group | 62.21 | 66.12 | 71.06 |
"Nausea level was measured using a 100-mm visual analog scale (VAS) to log the change in nausea levels between the study arms. No nausea is reported as 0 while worst nausea I have ever felt is reported at 100. Nausea was reported immediately prior to the procedure, 10 minutes following the procedure, and 30 minutes following the procedure." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 26 | 1 | 0 |
| Placebo Group | 26 | 12 | 5 |
"Pain level at a variety of time points will be measured using a 100-mm visual analog scale (VAS) to log the change in pain levels between the study arms. No pain is scored as 0 and worst pain imaginable is scored as 100. Pain will be assessed immediately prior to the procedure, at completion of the procedure (removal of the speculum), 10 minutes following the procedure, and 30 minutes following the procedure (at discharge)." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Prior to procedure | Speculum removal | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 20.76 | 44.10 | 30.64 | 20.89 |
| Placebo Group | 22.48 | 47.61 | 43.68 | 31.65 |
Participants reported if they vomited during the perioperative period to assess changes in vomiting incidences between the study arms. Vomiting is reported for the time periods of immediately prior to the procedure, 10 minutes following the procedure, and 30 minutes following the procedure. (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 4 | 5 | 5 |
| Placebo Group | 7 | 2 | 5 |
Participants were asked if they experienced dizziness, lack of muscle control, sleepiness or drowsiness, weakness or lack of energy, headache, or visual changes. (NCT02944656)
Timeframe: 10 and 30 minutes post procedure on Study Day 1
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dizziness 10 minutes post-procedure | Dizziness 30 minutes post-procedure | Lack of muscle control 10 minutes post-procedure | Lack of muscle control 30 minutes post-procedure | Sleepiness/drowsiness 10 minutes post-procedure | Sleepiness/drowsiness 30 minutes post-procedure | Weakness 10 minutes post-procedure | Weakness 30 minutes post-procedure | Headache 10 minutes post-procedure | Headache 30 minutes post-procedure | Vision changes 10 minutes post-procedure | Vision changes 30 minutes post-procedure | |
| Gabapentin Group | 27 | 19 | 9 | 5 | 38 | 30 | 33 | 20 | 5 | 4 | 9 | 3 |
| Placebo Group | 23 | 15 | 9 | 10 | 34 | 29 | 34 | 28 | 4 | 4 | 11 | 5 |
4 trials available for gabapentin and Pain, Procedural
| Article | Year |
|---|---|
Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial.
Topics: Dilatation; Double-Blind Method; Female; Fentanyl; Gabapentin; Humans; Midazolam; Nausea; Pain; Pain | 2023 |
Comparing the Effect of Gabapentin, Ketamine, Dexmedetomidine, and Entonox on Pain Control in Burn Wound Dressing.
Topics: Adult; Analgesics; Bandages; Blood Pressure; Burns; Debridement; Dexmedetomidine; Female; Gabapentin | 2020 |
Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Analgesics; Anesthesia, Local; Anesthesia, Obstetri | 2020 |
Gabapentin pretreatment for propofol and rocuronium injection pain: A randomized, double-blind, placebo-controlled study.
Topics: Adult; Amines; Analgesics; Androstanols; Anesthesia, General; Anesthetics, Intravenous; Cyclohexanec | 2018 |
4 other studies available for gabapentin and Pain, Procedural
| Article | Year |
|---|---|
A preliminary report on the effect of gabapentin pretreatment on periprocedural pain during in-office posterior nasal nerve cryoablation.
Topics: Adult; Aged; Ambulatory Care; Analgesics; Cryosurgery; Drug Administration Schedule; Female; Gabapen | 2020 |
The Pinderfields hospital pain management protocol for enzymatic debridement of burns wounds.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Conduction; Ane | 2020 |
Gabapentin for pain management after osmotic dilator insertion and prior to dilation and evacuation: A randomized controlled trial.
Topics: Abortion, Induced; Adult; Anesthetics, Local; Dilatation; Double-Blind Method; Female; Gabapentin; G | 2020 |
Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians.
Topics: Acetaminophen; Advance Care Planning; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Analgesic | 2020 |